Results 101 to 110 of about 38,769 (305)

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

, 2023
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear.
Carvalho, Davide, John J.V. McMurray, Vasques-Nóvoa, Francisco, Borges-Canha, Marta, João Pedro Ferreira, Francisco Vasques-Nóvoa, Leite-Moreira, Adelino, Marta Borges-Canha, Jennifer B. Green, Neves, João Sérgio, Adrian F. Hernandez, Stefano Del Prato, Green, Jennifer B., Del Prato, Stefano, McMurray, John J. V., Christopher B. Granger, Granger, Christopher B., Hernandez, Adrian F., Davide Carvalho, João Sérgio Neves, Lawrence A. Leiter, Adelino Leite-Moreira, Ferreira, João Pedro, Leiter, Lawrence A.   +23 more
core   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Journal of Obesity & Metabolic Syndrome, 2019
Background : Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk.
Sook Jung Lee, Kook Hyung Lee, Hyun Geong Oh, Hye Ji Seo, Soo Jin Jeong, Chong Hwa Kim   +5 more
doaj   +1 more source

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

, 2018
Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus ...
Biava A, Astrone P, Mainardi M, Gozzer C, Perna S, Rondanelli M, Solerte SB, Bacchio R, Spadaccini D   +8 more
core  

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed, Daniel Mølager Christensen, Milan Mohammad, Christian Torp‐Pedersen, Lars Køber, Emil Loldrup Fosbøl, Tor Biering‐Sørensen, Morten Lock Hansen, Mariam Elmegaard Malik, Nina Nouhravesh, Charlotte Anderrson, Morten Schou, Gunnar Gislason   +12 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
doaj   +1 more source

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model

, 2014
Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several ...
Dmitry eKolobkov, Oleg eDemin Jr, Tatiana Yakovleva, Oleg Demin, Oleg Demin, Oleg eDemin, Tatiana eYakovleva, Dmitry Kolobkov   +7 more
core   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

SGLT2 inhibitors as a novel senotherapeutic approach.

Cellular senescence is the permanent cessation of cell proliferation and growth. Senescent cells accumulating in tissues and organs with aging contribute to many chronic diseases, mainly through the secretion of a pro-inflammatory senescence-associated ...
Deelen, L, Ellison-Hughes, Georgina M, Lewis-McDougall, F, Yesilyurt-Dirican, ZE, Wang, Yi-Chian, Simm, Annika, Yeşilyurt Dirican, Zeynep Elif, Hafiz Abbas Gasim, Alia, Qi, C, Simm, A, Deelen, Laura, Wang, Y-C, Qi, Ce, Lewis-Mcdougall, Fiona, Ellison-Hughes, GM, Hafiz Abbas Gasim, A   +15 more
core   +1 more source